NewAmsterdam Pharma Company N.V (NAMS) Stock Price & How to Invest
Short answer
NAMS is NewAmsterdam Pharma, a late-stage biopharma whose value rests almost entirely on obicetrapib, an oral CETP inhibitor for lowering LDL cholesterol. Investing in it means underwriting a single, largely de-risked-but-not-yet-approved cardiovascular drug, funded by a large cash pile against ongoing losses.
NAMS stock price
As of 2026-07-08, NewAmsterdam Pharma Company N.V (NAMS) last closed at $35.83, up 65.6% over the past year. Over the past 52 weeks it has traded between $20.92 and $41.45.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or NewAmsterdam Pharma Company N.V's investor relations page. Walnut is informational, not investment advice.
What does NewAmsterdam Pharma Company N.V (NAMS) do?
NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company headquartered in Naarden, the Netherlands, and listed on Nasdaq under the ticker NAMS. Its lead candidate is obicetrapib, an oral, once-daily, low-dose CETP inhibitor being developed as a non-statin option (alone or as a fixed-dose combination with ezetimibe) to lower LDL cholesterol in patients who are not reaching targets on existing therapy. The company reported positive topline data from pivotal Phase 3 trials including BROADWAY, BROOKLYN and TANDEM, and is running the large PREVAIL cardiovascular outcomes trial; ex-US rights are partnered with the Menarini Group, and an earlier-stage Phase 2a program explores obicetrapib in Alzheimer's disease.
The investment picture is a classic late-stage biotech setup. As of the Q1 2026 report (reported May 2026), NewAmsterdam was still pre-commercial with only modest supply revenue (about $3.0 million in the quarter) and a net loss of roughly $48 million, but it held about $707 million in cash and marketable securities, giving it a multi-year runway to fund trials and a potential US launch. The market capitalization of around $4.4 billion prices in substantial commercial success for obicetrapib, so the stock behaves like an option on regulatory approval and the PREVAIL outcomes readout rather than on current financials.
What's driving NewAmsterdam Pharma Company N.V (NAMS)?
1. Obicetrapib approval path
Obicetrapib has posted positive pivotal Phase 3 data (LDL-C reductions of roughly 33% as monotherapy and about 49% combined with ezetimibe in reported studies), which underpins regulatory filings in the US and Europe. Approval as an oral, non-statin add-on would open a large addressable population of statin-treated patients who remain above LDL targets.
2. Oral, once-daily convenience versus injectables
The competitive pitch is a pill rather than an injection. Leading potent LDL-lowering drugs such as PCSK9 inhibitors are injectables, so an effective oral option could appeal to patients and prescribers who prefer a tablet, potentially widening use in primary care.
3. Deep cash runway and Menarini partnership
About $707 million in cash and marketable securities (as of Q1 2026) funds the ongoing PREVAIL outcomes trial and launch preparation without immediate financing pressure. The Menarini Group partnership provides ex-US commercialization reach and some non-dilutive economics.
4. Cardiovascular outcomes optionality
The PREVAIL cardiovascular outcomes trial could, if positive, extend the label from LDL lowering to demonstrated event reduction, which historically drives payer coverage and broader adoption. A favorable outcomes readout would be the single largest potential value inflection.
What are the risks to NewAmsterdam Pharma Company N.V (NAMS)?
The company is pre-commercial with negligible revenue, so the valuation depends on obicetrapib being approved and commercially adopted; a regulatory setback or a disappointing PREVAIL outcomes result would remove much of the thesis. CETP inhibitors as a class have a difficult history, with several prior candidates from large pharma failing in outcomes trials, which keeps skepticism elevated. Concentration is extreme because essentially all value sits in one molecule. Ongoing losses mean future capital raises and shareholder dilution are possible despite the current cash cushion. Commercial risk is real even after approval, given entrenched generics, injectable PCSK9 competitors, and payer access hurdles.
How is NewAmsterdam Pharma Company N.V (NAMS) valued? (approximate, MAY 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see NewAmsterdam Pharma Company N.V's investor relations page or your broker.
- Revenue (TTM): ~$22.6M
- Revenue (Q1 2026): ~$3.0M
- Net loss (Q1 2026): ~$48.4M
- EPS (Q1 2026): ~-$0.40
- Cash & marketable securities: ~$707M
- Market cap: ~$4.4B
The revenue base is tiny and consists mainly of product supply under the Menarini agreement, so traditional multiples are not meaningful. The stock trades as a clinical-stage bet where the roughly $4.4 billion market cap reflects expectations for obicetrapib rather than current sales. The large cash balance relative to the quarterly burn is the reason the company can fund trials and a potential launch without near-term financing.
Who competes with NewAmsterdam Pharma Company N.V (NAMS)?
Injectable PCSK9 inhibitors
Amgen's Repatha (evolocumab) and Novartis' Leqvio (inclisiran) are potent LDL-lowering injectables that can reduce LDL by roughly 50% or more on top of statins. They set the efficacy benchmark, though they require injection and can carry access and cost hurdles.
Oral non-statin lipid therapies
Esperion's Nexletol and Nexlizet (bempedoic acid, alone or with ezetimibe) plus generic ezetimibe are the closest oral competitors for patients not at target on statins. Obicetrapib would compete directly for this add-on oral niche.
Statins and emerging CETP or gene-based approaches
High-intensity generic statins remain the low-cost first-line standard, while newer approaches under study across the industry (other CETP programs, siRNA and gene-based lipid therapies) could reshape the dyslipidemia market over time.
How to invest in NewAmsterdam Pharma Company N.V (NAMS)
There are three common ways to get NAMS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so NAMS sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where NAMS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on NewAmsterdam Pharma Company N.V (NAMS)
NAMS is a one-asset, pre-commercial biopharma story: promising Phase 3 LDL data and a deep cash runway on one side, no meaningful revenue and binary regulatory and outcomes risk on the other.
More on NewAmsterdam Pharma Company N.V (NAMS)
Whether NAMS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is NAMS a buy?, and where the stock could go from here in the NAMS stock forecast.
For income investors, whether NAMS pays a dividend and how the payout looks is covered in does NAMS pay a dividend?
Build a basket around NAMS with Walnut
Use NewAmsterdam Pharma Company N.V as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does NewAmsterdam Pharma (NAMS) do?
+
It is a late-stage biopharmaceutical company developing obicetrapib, an oral CETP inhibitor for lowering LDL cholesterol in patients with cardiovascular disease and inherited high-cholesterol conditions. It is pre-commercial, meaning it does not yet sell an approved drug at scale.
What is obicetrapib?
+
Obicetrapib is an oral, once-daily, low-dose CETP inhibitor designed to lower LDL cholesterol, developed alone or as a fixed-dose combination with ezetimibe. In reported Phase 3 trials it lowered LDL-C by roughly 33% as monotherapy and about 49% in combination with ezetimibe.
Is NAMS profitable?
+
No. As of the Q1 2026 report (May 2026) the company had only about $3.0 million in quarterly revenue and posted a net loss of roughly $48.4 million. Like most clinical-stage biopharma, it spends heavily on trials while awaiting approval.
How much cash does NewAmsterdam have?
+
The company reported about $707 million in cash and marketable securities as of Q1 2026 (May 2026). That balance is meant to fund the PREVAIL outcomes trial and launch preparation, giving it a multi-year runway relative to its current burn rate.
Why is NAMS worth billions with almost no revenue?
+
Its market cap of around $4.4 billion (May 2026) reflects investor expectations that obicetrapib will be approved and widely used, not current sales. The stock effectively prices future commercial potential, which makes it sensitive to trial and regulatory news.
Who are NAMS's main competitors?
+
Injectable PCSK9 inhibitors like Amgen's Repatha and Novartis' Leqvio, oral options such as Esperion's bempedoic acid products, and low-cost generic statins and ezetimibe. Obicetrapib would compete as an oral add-on for patients not at LDL target.
What are the biggest risks with NAMS?
+
The value is concentrated in one drug, so a regulatory rejection or a negative PREVAIL cardiovascular outcomes result would be severe. CETP inhibitors as a class have a history of trial failures, and ongoing losses could require future capital raises and dilution.
What could move NAMS stock next?
+
Regulatory decisions in the US and Europe on obicetrapib, readouts from the large PREVAIL cardiovascular outcomes trial, commercial launch progress, and updates from its Menarini partnership are the key catalysts. Each is binary in nature, so the shares can be volatile around these events.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with NewAmsterdam Pharma Company N.V's investor relations page or your broker before making investment decisions.